Specialist Updates 
Rheumatology

JAK inhibitor ‘looks promising for ankylosing spondylitis’

A study shows improvements in patient pain and function with few serious adverse events, researchers say
Medicom Staff writer
0
13 November 2020
Save
ClosePlease login

AusDoc brings you the latest news from the American College of Rheumatology virtual congress 2020.

The Janus kinase inhibitor tofacitinib is shaping up as a potentially useful therapy for treatment of ankylosing spondylitis, according to results from a phase 3 randomised controlled trial.

Report

Harassment or bullying behavior
Contains mature or sensitive content
Contains misleading or false information
Contains abusive or derogatory content
Content that breaches the privacy of other individuals
Contains spam, fake content or potential malware

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .